Literature DB >> 28765931

LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia.

Tong-Feng Zhao1, Hui-Zhen Jia1, Zhen-Zhen Zhang1, Xiao-Su Zhao2, Yan-Fen Zou3, Wei Zhang4, Jun Wan1, Xiao-Fan Chen4.   

Abstract

Acute myelocytic leukemia (AML) is the most common type of acute leukemia. Long non‑coding RNAs (lncRNAs) serve an important role in regulating gene expression through chromatin modification, transcription and post‑transcriptional processing. LncRNA H19 was considered as an independent prognostic marker for patients with tumors. The expression of lncRNA H19 was identified to be significantly upregulated in bone marrow samples from patients with AML‑M2. Furthermore, it was demonstrated that the knockdown of lncRNA H19 resulted in increased expression of hsa‑microRNA (miR)‑19a/b and decreased expression of inhibitor of DNA binding 2 (ID2) in AML cells. The knockdown of lncRNA H19 inhibited the proliferation of AML cells in vitro, which could be partially reversed by ID2 overexpression. Furthermore, the results of the bioinformatic analysis revealed potential hsa‑miR‑19a/b‑3p binding sites in lncRNA H19 and ID2. Altogether, the results of the present study suggest that lncRNA H19 regulates the expression of ID2 through competitive binding to hsa‑miR‑19a and hsa‑miR‑19b, which may serve a role in AML cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765931     DOI: 10.3892/mmr.2017.7029

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  19 in total

Review 1.  Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.

Authors:  Yan Liu; Zhiheng Cheng; Yifan Pang; Longzhen Cui; Tingting Qian; Liang Quan; Hongyou Zhao; Jinlong Shi; Xiaoyan Ke; Lin Fu
Journal:  J Hematol Oncol       Date:  2019-05-24       Impact factor: 17.388

Review 2.  Non-coding RNAs: are they the protagonist or antagonist in the regulation of leukemia?

Authors:  Mrinnanda Bhattacharya; Ravi Kumar Gutti
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 3.  Pathogenic Mechanisms in Acute Myeloid Leukemia.

Authors:  Sohini Chakraborty; Christopher Y Park
Journal:  Curr Treat Options Oncol       Date:  2022-10-03

4.  Retracted Article: LncRNA ZEB2-AS1 regulates the drug resistance of acute myeloid leukemia via the miR-142-3p/INPP4B axis.

Authors:  Kai Wang; Jing Dai; Tao Liu; Qiong Wang; Yingxu Pang
Journal:  RSC Adv       Date:  2019-12-02       Impact factor: 4.036

Review 5.  Regulation of Human Breast Cancer by the Long Non-Coding RNA H19.

Authors:  Jordan Collette; Xuefen Le Bourhis; Eric Adriaenssens
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

6.  Prediction of microRNA-disease associations based on distance correlation set.

Authors:  Haochen Zhao; Linai Kuang; Lei Wang; Pengyao Ping; Zhanwei Xuan; Tingrui Pei; Zhelun Wu
Journal:  BMC Bioinformatics       Date:  2018-04-17       Impact factor: 3.169

7.  Prognostic values of the inhibitor of DNA‑binding family members in breast cancer.

Authors:  Xiao-Ling Zhou; Yan-Hong Ye; Shu-Ming Sun; Xiao-Feng Lu; Wei-Quan Liang; Chun-Fa Chen; Hao-Yu Lin
Journal:  Oncol Rep       Date:  2018-07-23       Impact factor: 3.906

8.  H19 overexpression promotes leukemogenesis and predicts unfavorable prognosis in acute myeloid leukemia.

Authors:  Ting-Juan Zhang; Jing-Dong Zhou; Wei Zhang; Jiang Lin; Ji-Chun Ma; Xiang-Mei Wen; Qian Yuan; Xi-Xi Li; Zi-Jun Xu; Jun Qian
Journal:  Clin Epigenetics       Date:  2018-04-10       Impact factor: 6.551

9.  The long non-coding RNA LOC285758 promotes invasion of acute myeloid leukemia cells by down-regulating miR-204-5p.

Authors:  Fangfang Xue; Haiyan Che
Journal:  FEBS Open Bio       Date:  2020-03-26       Impact factor: 2.693

10.  A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients.

Authors:  Fangce Wang; Xiaoxue Tian; Jie Zhou; Guangming Wang; Wenlei Yu; Zheng Li; Zhuoyi Fan; Wenjun Zhang; Aibin Liang
Journal:  Mol Med Rep       Date:  2018-06-06       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.